Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group

Nicolò Matteo Luca Battistia,⁎ Anna Rachelle Mislangb,⁎ Lisa Cooper c, Anita O'Donovand, Riccardo A. Audisioe, Kwok-Leung Cheung f, Regina Gironés Sarrió g, Reinhard Staude rh, Enrique Soto-Perez-de-Celis i, Michael Jaklitsch j, Grant R. Williams k, Shane O'Hanlonl, Mahmood Alam m, Clarito Cairon, Giuseppe Colloco, Luiz Antonio Gil Jr p, Schroder Sattar q, Kumud Kantilal q, Chiara Russo s, Stuart M. Lichtman t, Etienne Brain u, Ravindran Kanesvaran v, Hans Wildiers w

⁎ Breast Unit, Department of Medicine, The Royal Marsden NHS Foundation Trust, Breast Cancer Research Division, The Institute of Cancer Research, London, UK

⁎ Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Bedford Park, SA, Australia

Division of Aging, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Discipline of Radiation Therapy, Trinity College, Dublin, Ireland

Department of surgery, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

School of Medicine, University of Nottingham, Royal Derby Hospital Centre, Derby, UK

Department of Medical Oncology, Hospital Universitari i Politècnic La Fe, Valencia, Spain

Department of Internal Medicine V (Haematology and Oncology), Innsbruck Medical University, Innsbruck, Austria

Department of Geriatrics, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA

University College Dublin, St Vincent's University Hospital, Dublin, Ireland

Pfizer Oncology, Asia Pacific Region, Australia

National Integrated Cancer Control Program, Department of Health, Manila, Philippines

Policlínico A. Gemelli, Rome, Italy

Geriatric Division, São Paulo University, São Paulo, Brazil

College of Nursing, University of Saskatchewan, Regina, Canada

School of Pharmacy, University of East Anglia, Norwich, UK

Department of Medical Oncology, Centre Léon Bérard, Regional Comprehensive Cancer Centre, Claude-Bernard Lyon-1 University, Lyon, France

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Department of Medical Oncology, Institut Curie/Saint-Cloud, Paris, France

Department of Medical Oncology, National Cancer Centre Singapore, Singapore

Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium

a Breast Unit, Department of Medicine, The Royal Marsden NHS Foundation Trust, Breast Cancer Research Division, The Institute of Cancer Research, London, UK

b Division of Aging, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

c Discipline of Radiation Therapy, Trinity College, Dublin, Ireland

d Department of surgery, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

e School of Medicine, University of Nottingham, Royal Derby Hospital Centre, Derby, UK

f Department of Medical Oncology, Hospital Universitari i Politècnic La Fe, Valencia, Spain

g Department of Internal Medicine V (Haematology and Oncology), Innsbruck Medical University, Innsbruck, Austria

h Department of Geriatrics, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

i Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

j Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA

k University College Dublin, St Vincent's University Hospital, Dublin, Ireland

l Pfizer Oncology, Asia Pacific Region, Australia

m National Integrated Cancer Control Program, Department of Health, Manila, Philippines

n Policlínico A. Gemelli, Rome, Italy

o Geriatric Division, São Paulo University, São Paulo, Brazil

p College of Nursing, University of Saskatchewan, Regina, Canada

q School of Pharmacy, University of East Anglia, Norwich, UK

r Department of Medical Oncology, Centre Léon Bérard, Regional Comprehensive Cancer Centre, Claude-Bernard Lyon-1 University, Lyon, France

s Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

t Department of Medical Oncology, Institut Curie/Saint-Cloud, Paris, France

u Department of Medical Oncology, National Cancer Centre Singapore, Singapore

v Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium

ARTICLE INFO

Article history:
Received 29 June 2020
Accepted 10 July 2020
Available online 16 July 2020

Keywords:
Geriatric oncology
Older patients
COVID-19
SARS-CoV-2
Competing risks
Recommendations

ABSTRACT

The COVID-19 pandemic poses a barrier to equal and evidence-based management of cancer in older adults. The International Society of Geriatric Oncology (SIOG) formed a panel of experts to develop consensus recommendations on the implications of the pandemic on several aspects of cancer care in this age group including geriatric assessment (GA), surgery, radiotherapy, systemic treatment, palliative care and research.

Age and cancer diagnosis are significant predictors of adverse outcomes of the COVID-19 infection. In this setting, GA is particularly valuable to drive decision-making. GA may aid estimating physiologic reserve and adaptive capability, assessing risk-benefits of either providing or temporarily withholding treatments, and determining patient preferences to help inform treatment decisions. In a resource-constrained setting, geriatric screening tools may be administered remotely to identify patients requiring comprehensive GA. Tele-health is also crucial to ensure adequate continuity of care and minimize the risk of infection exposure.

⁎ Corresponding authors.

E-mail addresses: nicolo.battisti@rmh.nhs.uk (N.M.L. Battisti), Anna.Mislang@sa.gov.au (A.R. Mislang), lcooper5@bwh.harvard.edu (L. Cooper), Anita.O'Donovan@tcd.ie (A. O'Donovan), raudisio@doctors.org.uk (R.A. Audisio), k.cheung@nottingham.ac.uk (K.-L. Cheung), reinhard.stauder@med.ac.at (R. Stauder), enrique.sotop@incmsz.mx (E. Soto-Perez-de-Celis), mjaklitsch@bwh.harvard.edu (M. Jaklitsch), grwilliams@uabmc.edu (G.R. Williams), shaneohanlon@svhg.ie (S. O’Hanlon), Mahmood.Alam2@pfizer.com (M. Alam), schroder.sattar@uwsask.ca (S. Sattar), k.kantilal@pha.ca.ca (K. Kantilal), Chiara.RUSSO@lyon.unicancer.fr (C. Russo), LichtmaS@mskcc.org (S.M. Lichtman), Etienne.brain@curie.fr (E. Brain), ravindran.kanesvaran@nushealth.com.sg (R. Kanesvaran), hans.wildiers@uzeleven.be (H. Wildiers).

https://doi.org/10.1016/j.jgo.2020.07.008
1879-4068/© 2020 Elsevier Ltd. All rights reserved.
1. Introduction

The COVID-19 pandemic requires the implementation of individualized approaches for the management of cancer in older adults. As of June 2020, there were more than 10 million cases and over 500,000 deaths worldwide [1,2]. The actual cumulative death toll from COVID-19 is expected to be higher as reporting varies within each country. While the virus affects people of all ages, data have consistently shown that mortality is higher with increasing age and comorbidities [3–6]. The case fatality rates (CFR) in patients aged less than 70 years were reported as 0.3–3.5% [7,8]. This is in contrast to the CFR of 8% in patients aged 70–79 years and around 15% in those aged over 80 years in China [7]. In Italy, epidemiological data shows that the mean age of patients dying from COVID-19 was 80 years [9], with CFR rising with increasing age beyond 70 years: 12.5% (70–79), 19.7% (80–89) and 22.7% (over 90) [8]. In the United States, the death rate in New York City among patients aged 75 years or older was more than 1511 per 100,000 population [10].

COVID-19 represents an additional competing risk factor to consider when undertaking therapeutic decisions for older adults with cancer (Fig. 1). The International Society for Geriatric Oncology (SIOG) advocates for integrating geriatric assessment (GA) to drive decision-making in the management of older adults with cancer, especially during the COVID-19 pandemic.

Older age and comorbidities such as cardiovascular disease, diabetes, chronic respiratory disease, chronic renal impairment, and cancer have been shown to increase risk for worse outcomes from COVID-19. [11,12] In many older patients with cancer where management could be challenging, the risks of morbidity and mortality from acquiring COVID-19 must be considered when assessing risks and benefits of the decision to treat. Currently, personalized care should be the norm in treating older patients with cancer; with COVID-19, it becomes even more imperative that such an approach is followed to avoid the risk of over- or under-treatment [13] and minimize the risk of adopting an ageist approach.

In order to mitigate the negative impact of COVID-19 on the management of cancer in older adults, SIOG has brought together a COVID-19 Working Group including members from different continents and with different specialties (surgery, radiation oncology, medical/geriatric oncology, geriatrics, haematology, nursing, pharmacy) to develop recommendations and an action plan based on expert opinion and evidence related to geriatric oncology and applied to these circumstances.

2. Impact of the COVID-19 Pandemic on Older Adults With Cancer

Cancer is a disease of older adults. On the other hand, baseline information from epidemiological data on specific cancer types, stage, and treatment at the time of COVID-19 infection are lacking. In the recently published COVID-19 and Cancer Consortium (CCC19) cohort, the median age of patients with cancer and COVID-19 was 66 years, and 56% were aged 65 years and older [14]. Mortality was found to be closely associated with age, with patients aged 65–74 and over 75 years having a relative risk of death of 11% and 25% respectively, compared to 6% for patients below the age of 65 years. In the TEREVOLT cohort of patients with thoracic malignancies and COVID-19, age was also closely

![Fig. 1. Factors to consider in treatment decision-making for older patients with cancer during the COVID-19 pandemic.](image-url)
associated with increased risk of death, with patients aged 65 years and older [OR 1.88, 95% CI 1.0–3.6] [15].

In general, COVID-19 is acquired by transmission of a respiratory virus via close contact, droplet spray or aerosol, with the duration of viral stability and viability maintained depending on various objects or surfaces [16]. Most local and national health organizations worldwide have implemented various means to mitigate viral transmission and allocate resources appropriately. Primary and secondary prevention measures have included home confinement and social distancing of patients with cancer, limiting their hospital visits where the risk of acquiring COVID-19 is high, and reducing iatrogenic immunosuppression and treatment-related toxicities, which often leads to inpatient admissions that could put pressure on already stretched resources [17]. Goals of care should be established early and documented clearly. These should be revisited periodically and must also include individualized discussions on advance care planning that should be based on the individual circumstances, particularly in the context of a pandemic.

Several geriatric-focused issues have been identified as a result of imposed quarantine and social distancing, including: 1) feelings of estrangement and neglect due to limited access to news or information, friends and family, particularly when access to digital technology is lacking; 2) decline in communication and comprehension not only due to isolation but also from wearing masks and face shields, more particularly so for hard-of-hearing patients who rely on lip reading and non-verbal cues; 3) loss of autonomy and ensuing dependency on others to provide basic needs such as medicines, food and other home supplies due to travel restrictions or lack of access to transportation; 4) disruption of established community support for seniors such as cleaning, shopping, and home maintenance to aid them to cope with daily life; 5) increased risk of deconditioning in the outpatient setting and following acute medical admissions. In addition, social restrictions and shielding can lead to significant decrease in physical activity which, in turn, can contribute to or accelerate loss of muscle mass and bone density, as well as mobility and functional impairment in older adults; [18,19] and 6) institutionalized patients, such as those in a nursing care facility are at higher risk of acquiring COVID-19 infection, increased feelings of abandonment, as well as mental health problems [20,21].

The risk of delirium is especially important and underestimated, called by some experts the “silent epidemic within the pandemic.” [22,23] Leading authorities on delirium have found that altered mental status may be one of the first signs of COVID-19 infection among vulnerable older adults, and that the current state of hospitals and other healthcare settings is becoming more “deliriogenic” as they restrict visitors, require all staff members to wear personal protective equipment (PPE), and minimize patient interaction to avoid exposure [24]. In these times, it is paramount to evaluate in the out-patient setting and stratify the risk of delirium in patients prior to administering any anticancer treatment. Hence, the impact of social isolation as a result of recommendations on physical distancing, risk of delirium, and decisions regarding anticancer treatment are important issues to assess and proactively address [25].

3. Geriatric Assessment

Older patients with underlying comorbidities have increased disease severity and mortality from COVID-19 [26]. Chronological age alone should not drive decisions on whether or not to provide life-saving treatments during the pandemic [27], and yet, older patients with cancer are likely to be doubly disadvantaged as health systems are overwhelmed.

Prior to this pandemic, frailty had been increasingly adopted as a superior predictor of adverse outcomes over chronologic age for older adults in multiple clinical settings. In the oncology setting, frailty has been proven to predict toxicity from treatment and mortality, and leading cancer societies have recommended GA to gauge frailty prior to treatment in older adults to assess such risks [28–30]. The decision to treat older patients with cancer is best guided with GA and discussed in a multidisciplinary setting to help care providers determine the best treatment options, predict treatment-related toxicities, and establish ongoing management for cancer and other competing risks [31]. GA is particularly valuable in a context where competing risks are more prevalent. GA may estimate physiologic reserve and adaptive capability, assess risk-benefits of either providing or temporarily withholding treatments, and determine patient preference to help inform treatment decisions.

Different tools, such as the Clinical Frailty Scale and the Frailty Index have been proposed to screen and stratify frailty in the setting of COVID-19 [32,33]. However, others have highlighted that their use has not been validated in these circumstances, and advocate for cautious implementation in the context of the pandemic as clear evidence is limited [34,35]. Additional concerns about the widespread use of these tools include the need for standardized training to ensure accuracy in the assessment as well as a clear understanding of limitations and appropriateness of using these tools to inform, and not replace personalized discussions and care recommendations for older adults. In the majority of cases, in the interest of time to limit visits and infection exposure for professionals and patients, geriatric screening may be sufficient to identify the risk of frailty in some way. The selection of patients most likely to benefit from a multi-domain GA is a major challenge.

We recommend using screening tools that can be self-administered by patients, such as the G8 screening tool or Vulnerable Elders-13 Survey (VES13) [36]. Once patients are identified as high-risk for frailty, we recommend further assessment by clinicians with geriatric expertise via telemedicine for assessment of function, cognitive reserve, mood and delirium, nutritional status, and social support using validated tools.

Telehealth has been implemented widely across settings in the midst of the current pandemic, and has been shown to be an effective modality [37] even for vulnerable populations [38]. Oncology-specific GA can also be conducted via telemedicine. One example was outlined by the University of Rochester Specialized Oncology Care and Research in the Elderly (SOCARE) and the Ohio State University group. They presented a framework for multi-domain GA that can be conducted mostly by telephone. This telemedicine version of the GA includes a pre-visit phone screen to identify areas of vulnerability and help guide decision-making for older adults with cancer (Table 1) [39].

More research on conducting GA in a time-efficient manner is needed and decision-making should incorporate patients’ preferences and goals, especially in these times of heightened risk and uncertainty. Paired with the information derived from a GA, goal-concordant care is paramount in partnership with patients and caregivers in weighing the risks of COVID-19 exposure and antinecancer treatments against the risks of delaying such treatment.

4. Surgery

Decision-making should be individualized and take into account the potential risk of pursuing, delaying or omitting surgery or choosing different surgical approaches. (Table 2). For example, open and endoscopic techniques have different intensive care requirements, whereas some operations may avoid or delay the need of alternative treatments (e.g., neoadjuvant chemotherapy) which may be less safe in the context of the pandemic. Along with patients’ fitness and comorbidities that may influence postoperative outcomes, clinicians should consider factors related to the tumor, such as its morbidity and mortality and the presence or absence of ongoing cancer-related symptoms, and those associated with the planned surgical procedure being considered, in order to ensure the most secure and safest approach to achieve local disease control.

Elective surgical procedures scheduled at inpatient facilities may be delayed [40,41]. Nonetheless, the definition of “elective” is sometimes debatable. Apart from emergency operations, any essential procedures
Abbreviations: GA: geriatric assessment; OARS: Older Americans Resources and Services; pancreatic, liver, bladder, renal, lung and brain tumors [42,43]. Selected may include those where a delay by two or three months can signi cant impact on outcomes in a retrospective analysis from a single academic hospital [46]. Less toxic systemic treatment such as endocrine therapy or radiotherapy may be considered means to delay surgery in selected cases, as discussed below. Nonetheless, predicting when the outbreak will end, even at a local level remains a significant challenge.

As surgery gets delayed, prehabilitation may be adopted during pandemic to ensure that fitness to treatment is achieved or maintained. For example, a 60-day delay to surgery for stage I-II breast cancer patients had no detrimental impact on outcomes in a retrospective analysis from a single academic hospital [46]. Less toxic systemic treatment such as endocrine therapy or radiotherapy may be considered means to delay surgery in selected cases, as discussed below. Nonetheless, predicting when the outbreak will end, even at a local level remains a significant challenge.

As surgery gets delayed, prehabilitation may be adopted during pandemic to ensure that fitness to treatment is achieved or maintained while waiting, to minimize post-op morbidity and mortality, which may include physical exercise, nutritional support, as well as management of comorbidities, health risks and psychosocial factors [47]. However, such intervention should be implemented in the context of the recommended strategies to minimize the risk of COVID-19 transmission.

In certain circumstances, omitting surgery may be appropriate when the impact on symptoms and survival is minimal or if a safe and effective alternative systemic treatment is available. For example, the use of primary endocrine therapy for older patients with early-stage ER-positive, HER2-negative breast cancer is supported by evidence demonstrating no positive impact of surgery on overall survival (OS) [48–50].

5. Radiotherapy

Similarly, the use of radiation therapy (RT) in older patients should be prioritized based on its intent, expected benefits, and tumor characteristics in the context of patients’ fitness and preference (Table 2). In the older age group, social issues, traveling constraints, daily hospital visits, and patients’ concerns regarding exposure may represent significant challenges requiring careful consideration.

Furthermore, radiation dose, fractionation and techniques should be optimized and adapted to the emergency context. In the curative setting, hypofractionated regimens and shorter schedules might be preferable [51]. For example, a short course of neoadjuvant RT should be favored over a more prolonged course of chemoradiotherapy for older patients with locally advanced rectal cancer, with the aim of minimizing the need for hospital attendance and the chances of myelosuppression [52]. For early breast cancer, 15% of patients enrolled in the FAST Forward study experimental arm were aged 70 years and older and this trial confirmed non-inferiority of a shorter course of adjuvant RT (26 Gy in 5 fractions) compared with a standard regimen of 40 Gy in 15 fractions [53]. Modest hypofractionation can also be considered for patients with early prostate cancer [54]. Such regimens are appropriate alternatives to minimize the risk of infection exposure in older patients. Despite its role still being debated, intraoperative RT may be considered to spare older adults undergoing surgery from having subsequent outpatient appointments [55,56]. Specific guidance is available on RT regimens for patients with hematological malignancies [57].

In the palliative setting, patients should be offered the smallest number of fraction to minimize the need to attend the hospital and potential exposure to infection. For bony pain relief, a single 8 Gy fraction should be favored as equally effective as multiple fractions [58]. A single fraction also can be offered in case of metastatic cord compression [59]. The role of whole brain RT for the management of brain metastases remains controversial as medical treatments might already be beneficial with regard to symptom control [60]. In contrast, stereotactic body RT (SBRT) might still be appropriate in the context of its better safety profile, which is particularly relevant in frail and older individuals [61].

RT should be delayed in the absence of any significant impact on cancer management outcomes. On the other hand, in cases of curative intent or rapidly progressive disease, the risks of delaying RT might

Table 1

| GA domain | Modified tele-health SOCare GA |
|-----------|--------------------------------|
| Functional status | OARS: instrumental activities of daily living |
| 1) Can you use the telephone? | |
| 2) Can you get to places out of walking distance? | |
| 3) Can you go shopping for groceries or clothes (assuming you have transportation)? | |
| 4) Can you prepare your own meals? | |
| 5) Can you do your housework? | |
| 6) Can you take your own medicines | |
| 7) Can you handle your own money? | |
| 8) Can you walk about one block? |
| Fall history | In the past year, have you fallen down? |
| 1) About how long ago was your most recent fall? |
| Fatigue rating | 1) Do you experience fatigue and weakness? |
| 2) If yes, rate your fatigue on a scale of 1–10 (10 = severe, 0 = absence). |
| Hearing | 1) How is your hearing (with a hearing aide, if needed)? |
| 2) If hearing is fair to totally deaf, how much does it interfere with activities? |
| Comorbidities | Comorbidity review |
| Completed by geriatric oncologist during visit |
| Polypharmacy | Medication review |
| Nurse Navigator confirmed current medications and provided list to SOCARE pharmacist for review and potential recommendations |
| Nutrition | Weight loss |
| 1) Have you lost weight in the past 6 months (involuntarily)? |
| 2) What is your weight now? |
| 3) What was your weight 6 months ago? |
| Cognition | Blessed orientation memory concentration |
| Conducted in person by occupational therapist during visit |
| Social support | 1) Who do you live with? |
| 2) Who is your main social support? |
| Psychological status | PHQ-2 |
| 1) In the last two weeks, how often have you been bothered by |
| (0 = Not at all, 1 = Several days, 2 = More than half the days, 3 = Nearly every day) |
| a) Limited interest/pleasure in doing things? |
| b) Feeling down, depressed, or hopeless? |

Abbreviations: GA: geriatric assessment; OARS: Older Americans Resources and Services; MOS: Medical Outcomes Survey; PHQ-2: Patient Health Questionnaire 2.
| Care domains | Recommendations | Practical examples |
|-------------|----------------|--------------------|
| General interventions | Maintain physical distancing to reduce risk of exposure and viral transmission | Self-administered screening tools: G8, VES-13 |
| | Implement strict infection control policies in residential care facilities and hospitals, and minimize or discourage all non-essential visits | SOCARE team telehealth-geriatric assessment |
| | Deploy telehealth care via telephone or video link to protect both the patient and the clinician and provide continuity of care despite social containment | |
| | Encourage digital literacy and provide access to online technologies to maintain social network with family, friends, support workers and care providers | |
| | Implement a coordinated and pragmatic treatment journey to rationalize and/or minimize hospital appointments | |
| | Identify early, periodically re-evaluate and clearly document the goals of care | |
| | Consider advance care planning discussions where appropriate | |
| Geriatric assessment | Implement remote geriatric screening as a more time- and resource-efficient strategy to select older patients requiring a more comprehensive assessment | |
| | Conduct geriatric assessments by implementing telehealth via platforms in compliance with local electronic health care regulations | Hypofractionation for breast cancer |
| | Adopt a “virtual” geriatric-focused multidisciplinary team approach through the use of videoconferencing platforms to enable tumor board meetings in compliant with local regulations | Short-course neoadjuvant radiotherapy for rectal cancer |
| | Prioritize surgery management based on patients’ global health status and wishes, setting (curative versus palliative), type of surgery and risk of complications, need for general or local anesthetics, expected recovery time, availability of hospital resources, presence of cancer-related symptoms | Single-fraction radiotherapy for palliative purposes |
| | Prioritize surgical management based on patients’ global health status and wishes, setting (curative versus palliative), class of agents, expected toxicities, availability of hospital resources, presence of cancer-related symptoms | Stereostatic radiotherapy for early non-small cell lung cancer or central nervous system metastases |
| | Delay noncritical radiotherapy within disease-specific safe time intervals in the adjuvant setting especially if systemic treatment options are available | Consider ADT to delay radiotherapy for early prostate cancer |
| | Omit radiotherapy if no clear survival or symptom control benefit especially if safe systemic or radiotherapy options are available | Avoid radiotherapy boost for early breast cancer |
| | Prioritize systemic treatments based on patients’ global health status and wishes, setting (curative versus palliative), class of agents, expected toxicities, availability of hospital resources, presence of cancer-related symptoms | CARG or CRASH chemotherapy toxicity prediction tools |
| | Implement the use of chemotherapy toxicity prediction tools | Neoadjuvant endocrine therapy for HR-positive, HER2-negative early breast cancer, particularly for those with lobular histology or Luminal-A like subtype |
| | Implement home delivery services for oral agents, home blood service and home treatment administration if available | Primary endocrine therapy for HR-positive, HER2-negative early breast cancer |
| | Prescribe primary G-CSF prophylaxis to limit risk of myelosuppression | Substituting oral for intravenous preparation, i.e. oral vinorelbine for day 8 treatment; capecitabine for fluorouracil for the treatment of GI malignancies |
| | Delay noncritical systemic treatments within disease-specific safe time intervals in the adjuvant setting | Consider omitting adjuvant chemotherapy for patients with low-risk HR-positive, HER2-negative breast cancer and in low-risk Stage II colorectal cancer |
| | Omit systemic therapy if no clear survival or symptom control benefit | Consider 3 over 6 months adjuvant treatment for Stage 3 colorectal cancer |
| | Avoid oxaliplatin in Stage 3 colorectal cancer where the benefit in older patients is lacking | Omit oxaliplatin in Stage 3 colorectal cancer where the benefit in older patients is lacking |
| | Consider ADT to delay surgery and/or radiotherapy for early prostate cancer | Consider ADT to delay surgery and/or radiotherapy for early prostate cancer |
| | Preference for a less frequent treatment dosing schedule, i.e. CAPOX vs. FOLFOX; 6-weekly vs. 3-weekly pembrolizumab | Preference for a less frequent treatment dosing schedule, i.e. CAPOX vs. FOLFOX; 6-weekly vs. 3-weekly pembrolizumab |
| Surgery | Prioritize radiation therapy approaches based on patients’ global health status and wishes, setting (curative versus palliative), fractionation and dosing, risk of side effects, availability of hospital resources, presence of cancer-related symptoms | |
| Radiotherapy | Prioritize radiation therapy approaches based on patients’ global health status and wishes, setting (curative versus palliative), fractionation and dosing, risk of side effects, availability of hospital resources, presence of cancer-related symptoms | |
| Systemic therapy | Prioritize systemic treatments based on patients’ global health status and wishes, setting (curative versus palliative), class of agents, expected toxicities, availability of hospital resources, presence of cancer-related symptoms | |
| | Implement the use of chemotherapy toxicity prediction tools | Primary endocrine therapy for HR-positive, HER2-negative early breast cancer |
| | Implement home delivery services for oral agents, home blood service and home treatment administration if available | |
| | Prescribe primary G-CSF prophylaxis to limit risk of myelosuppression | |
| | Delay noncritical systemic treatments within disease-specific safe time intervals in the adjuvant setting | Primary endocrine therapy for HR-positive, HER2-negative early breast cancer |
| | Omit systemic therapy if no clear survival or symptom control benefit | |
| | Avoid oxaliplatin in Stage 3 colorectal cancer where the benefit in older patients is lacking | |
| Palliative Care | Discuss advance care plans to determine care preferences and goals, such as do not attempt cardiopulmonary resuscitation orders, enteral feeding, intubation, or dialysis | |
| | Use telemedicine and videoconferencing to facilitate communications with older persons in home settings and institutions as appropriate and evaluate their efficacy | |
| | Use palliative care techniques to communicate with families and support older patients dying in critical and palliative care settings | |
| | Provide WHO recommended infection control procedures and other guidance on PPE, as well as psycho-social and spiritual support to staff in hospitals, nursing homes, hospices and community settings to ensure well-being and resilience | |
| | Avoid sedentary lifestyle by integrating home-based physical exercises into daily routine | |
| | Either or a combination of 150 min of moderate intensity or 75 min of vigorous intensity of physical activity per week, depending on the pre-existing level of function | |
| | Schedule short active breaks during the day, which may include standing every hour, walk around the block or walk several times inside the house, or follow regimen from online exercise class | |
| | Practice meditation, mindfulness and deep breathing exercise | |
| | Integrate cognitively stimulating activities, i.e. puzzles, reading, or board games | |
| | Monitor nutrition, avoid substance abuse, and control comorbidities by coordinating with the primary care provider | |

Abbreviations: VES-13: Vulnerable Elders Survey-13; HR: hormone receptor; HER2: human epidermal growth factor receptor 2; CARG: Cancer and Aging Research Group; CRASH: Chemotherapy Risk Assessment Scale for High age; G-CSF: granulocyte colony-stimulating factor; ADT: androgen deprivation therapy; SOCARE: University of Rochester Specialized Oncology Care and Research in the Elderly; WHO: World Health Organization.
outweigh the risks of COVID-19 exposure and infection [62]. Patients already undergoing RT should be offered a discussion about the risks and benefits of continuing it based on individual goals of care [51,63].

For patients with early-stage breast cancer, RT can be safely delayed for up to five months for those receiving chemotherapy followed by endocrine therapy [64]. RT can be delayed by 3–6 months for patients with early prostate cancer in case of low-risk disease while aiming for either active surveillance or upfront androgen deprivation therapy (ADT) [65,66]; in cases of high-risk disease, RT can be delayed for up to 2–3 months while starting patients on ADT [67].

In the curative setting, survival gains may be modest in older patients in the context of competing risks of mortality including COVID-19 and careful consideration should be given to balancing risks and benefits. Treatments reducing the risk of locoregional recurrence in the absence of any survival improvement may be appropriately omitted [68]. For older patients with low-risk disease, breast radiotherapy can be safely omitted [69,70]. Also, adding a RT boost for patients with early-stage breast cancer does not improve survival outcomes and might cause additional toxicities in older patients. In the palliative setting, RT should be pursued when any other options, including medical treatment (such as analgesia and bisphosphonates for bone pain), have been exhausted.

Finally, in the context of the pandemic, RT in the form of either SBRT or conventional fractionation may represent a reasonable alternative to surgery in selected cases, such as older patients with stage I-II non-small cell lung cancer [71]. SBRT may be valuable in this setting in view of the limited number of fractions required (usually 1–5) to spare patients potentially prolonged admission and postoperative complications. Combined data from two trials comparing SBRT with surgery showed better 3-year overall survival for SBRT and no differences in locoregional and distant recurrence, although this analysis should be interpreted with caution in view of the small number of patients enrolled [72]. The practicalities of reducing infection risk within the radiotherapy department and educating patients on appropriate safety measures is discussed in detail elsewhere [68,73].

6. Systemic Treatment

The potential benefits of systemic treatments (including chemotherapy, targeted therapy, endocrine therapy and immunotherapy) in terms of tumor control are unchanged during a pandemic. However, risks may be higher especially for treatments causing myelosuppression or requiring frequent hospital visits and increased infection exposure. Nonetheless, the balance of risks and benefits remains uncertain as there is no evidence suggesting that changing or withholding systemic treatment is beneficial during a pandemic (Table 2) [74]. Therefore, decision-making should again be individualized based on consideration of tumor biology, type of systemic therapy, patients’ general health status and preferences in the context of the presence of cancer-related symptoms (in cases of active disease), local prevalence of COVID-19, the availability of healthcare system resources, and the risk of infection exposure. Guidelines focusing on delivering specific systemic treatments during the pandemic are also available [63].

Models based on GA have been developed to predict chemotherapy toxicity and may aid therapeutic decisions in older patients. Therefore, their implementation is particularly appropriate in the context of the ongoing COVID-19 pandemic. The Cancer and Aging Research Group (CARG) model takes into account age, type of cancer, proposed chemotherapy regimen, renal and hematologic function, hearing, along with GA domains such as ability to take medications, physical activity and social activity [75,76]. The Chemotherapy Risk Assessment Scale for High age (CRASH) is based on the specific chemotherapy regimen being considered as well as laboratory values (creatinine, albumin, hemoglobin, lactate dehydrogenase, liver function tests) and assessments of functional, mental, and nutritional status [77].

In the curative setting, chemotherapy should be considered if indicated and in the presence of clear survival benefits, which may be less established in the older age group [78]. If possible, a shorter treatment duration should also be considered. In the palliative setting, shared decision-making should also take into account the hazards of worsening symptoms and functional status, which may lead to losing the opportunity to treat [79]. Discontinuing chemotherapy may be an option for some patients with low volume disease or after attaining ongoing disease, especially if alternative non-myelosuppressive agents are available, such as endocrine therapy for hormone receptor-positive breast cancer patients.

In general, evidence-based chemotherapy regimens that require less frequent dosing should be favored in order to minimize the need for hospital attendance, especially in cases of high local prevalence of COVID-19. If available and appropriate, oral agents should be considered in place of intravenous treatments, as long as there is evidence to support this change. For example, capecitabine can substitute for fluorouracil in managing colorectal malignancies without compromising outcomes [80]. Whenever possible, physicians should attempt to utilize existing evidence to choose strategies shown to be of similar efficacy (in both the younger and older population) over more intensive and/or toxic regimens. Relevant examples include offering three instead of six months of adjuvant chemotherapy for patients with stage III colon cancer [81], utilizing a 40% dose reduction of combined oxaliplatin and capcitabine chemotherapy for frail or older patients with metastatic gastric cancer [82], or opting for best supportive care alone over chemotherapy for vulnerable/ frail patients with advanced lung cancer [83].

Primary prophylaxis with granulocyte colony-stimulating factors is advisable for patients receiving chemotherapy in view of the higher risk of myelosuppression in older individuals [84–86]. Home-drawn blood service can also be considered, along with setting up courier drug delivery and home treatment administration systems to minimize the need to travel to the hospital. The National Comprehensive Cancer Network (NCCN) has issued a toolkit to facilitate the shifting of systemic anticancer treatments for hematologic malignancies from inpatient to outpatient setting [87].

In older patients with hematologic malignancies, the risk of disease and treatment-related lymphopenia and neutropenia should also be considered and integrated in decision-making [88]. Likewise, the need for anti-CD20 monoclonal antibodies should be critically evaluated in view of the adverse impact of lymphopenia on COVID-19 outcomes [88]. Data are limited on the impact of immunotherapy on COVID-19 and potential risks and benefits should be balanced and personalized in older patients. Nonetheless, the less frequent dosing of some immunotherapy agents is particularly attractive in this context to minimize the need for hospital visits.

Systemic treatment given in the adjuvant setting can be delayed within the accepted timing for each tumor type. For example, for patients with colorectal or lung cancer, it can be safely postponed for up to 8 weeks [89,90], and for those with breast cancer for up to 12 weeks after surgery [91]. Older patients should not be denied systemic treatments on the basis of chronological age alone. Instead, the decision to treat should consider individual circumstances that are likely to influence a significant impact on survival or symptom control, including life expectancy, comorbidities and tumor biology, in the context of patients’ preferences.

Systemic therapies may also be considered as effective means to delay surgery in selected cases. A neoadjuvant endocrine approach is particularly valuable for older patients with estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, as aromatase inhibitors are associated with low toxicity and reasonable response rates at 3–4 months [92]. ADT may also be considered preoperatively for selected older adults with prostate cancer, although evidence on its impact on radical resection rates is still scarce [93,94]. Despite the benefits, the use of upfront chemotherapy, e.g. taxanes, in the pandemic setting is more questionable in view of the
higher risk of myelosuppression and infections in the older age group, the need for more hospital visits and clinician-patient contact, not unless the risks are outweighed by the benefits of rapid disease control to allow a curative resection [84,85,95], although patients’ preferences remain crucial [96].

7. Palliative Care

Despite the scarcity of health resources brought on by the pandemic, attention needs to be paid for the provision and maintenance of palliative care services. COVID-19 restrictions and physical distancing guidelines have resulted in reduced access to available information, care and support from families and friends, as well as social and personal care services that allow older persons, including those living with disabilities, to cope at home. Older persons with cancer may present with symptoms associated with their malignancy or treatment toxicity, exacerbation of comorbidities or COVID-19 that may require hospital admission for critical care and/or referral to palliative care.

Early discussion of advance care plans should be implemented to determine patients’ preferences and treatment goals. Telemedicine can also facilitate communication with older adults in home settings and institutions as appropriate. Clinicians should also ensure prompt and adequate communication with families and support older patients during end of life care in critical and palliative care setting, including psycho-social and spiritual support. Infection control procedures should apply also to palliative care settings. The demand for palliative care services (at home or residential care facilities, in hospitals or hospices) may increase and this should be adapted to respond rapidly and flexibly during the pandemic [97], within the scope of availability of staff and other health-care resources.

8. Survivorship

Cancer survivors include people who have completed initial treatment with no evidence of active disease or those living with progressive disease who may be receiving cancer treatment but are not in the terminal phase of illness [98]. Older people account for more than two-thirds of cancer survivors [99]. However, COVID-19 may disproportionately impact older cancer survivors’ physical health and psychosocial wellbeing, which may lead to unintended consequences in the long-term [100]. Despite social and outdoor activities being on hold due to COVID-19 restrictions, it is recommended to avoid sedentary lifestyle by maintaining physical activity by integrating exercise into the daily routine [101].

Delivery of high-quality, tailored, person-centred survivorship care to address the unique needs of older cancer survivors during the pandemic is challenging. Nonetheless, as evidence here is still lacking, the recommendations valid for the general population should apply also to older cancer survivors.

9. Research

The COVID-19 pandemic presents a further major barrier to participation in clinical trials for older adults with cancer, who are already under-represented in oncology studies [102]. Screening and/or enrollment for certain clinical trials have been either halted or prioritized in several research programs worldwide [103]. Nonetheless, where feasible, it is imperative to continue facilitating the access of older patients to clinical trials to minimize the impact of the pandemic on the expansion of knowledge relevant for this age group while complying with current regulations and limiting the consequences on study integrity [104,105]. The US Food and Drug Administration and the European Medicines Agency have issued specific recommendations on this topic [106,107].

In addition, more evidence on the impact of the COVID-19 pandemic in older adults with cancer is warranted. With many preventive (i.e. COVID-19 vaccine) trials underway, inclusion of eligible older patients with cancer should be considered. As recently outlined by the CARC investigators [25], multicenter and international collaborations and novel methods of rapid dissemination will be crucial to elucidate the interaction between global health measures (rather than age alone) and oncological outcomes, along with endpoints particularly meaningful for older adults, such as function and quality of life.

10. Recommendations and Action Plans

COVID-19 is an emerging and rapidly evolving condition that warrants tailored care and assessment depending on the disease prevalence. As society grapples with the pandemic and how best to deliver cancer care in older patients, there is an urgent need to act now to protect the vulnerable and mitigate the projected negative outcomes in this age group. As this is unlikely to be the last pandemic that we will encounter, it is imperative to take this unique opportunity to learn and devise management plans for both present and future use. It should also be acknowledged that the previously mentioned recommendations may lead to different implementation depending on the stage of the pandemic. Whilst data are still emerging and median follow-up from published trials is short to make robust conclusions, the SIoG Working Group has developed a number of recommendations on the management of older adults with cancer and future directions, which are outlined in Table 2.

Acknowledgments

Dr. Battisti would like to acknowledge the support of the Criddel Ross Smith Charitable Trust and the NIHR Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK. Dr. Lichtman is supported by the NCI Cancer Center Support Grant (P30CA008748).

References

[1] Available from: https://www.worldometers.info/coronavirus/.
[2] Organization, WH. Novel coronavirus (COVID-19) situation. Available from:https://www.who.int/emergencies/diseases/novel-coronavirus-2019;
[3] Kudrerer NM, et al. Clinical impact of COVID-19 on patients with cancer (CC19): a cohort study. Lancet 2020;395(10241):1907–18. https://doi.org/10.1016/S0140-6736(20)31173-9
[4] Li Y, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 2020;395(10241):1919–26. https://doi.org/10.1016/S0140-6736(20)31173-9
[5] Liang W, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21(3):335–7.
[6] Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054–62.
[7] The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China, Zhonghua Liu Xing Bing Xue Za Zhi 2020;41(2):145–51.
[8] Livingston E, Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA 2020;323(14):1335.
[9] Sanità SD. Characteristics of SARS-CoV-2 patients dying in Italy [Report based on available data on May 28th, 2020]. 2020.
[10] Death rates for COVID-19 in New York City as of June 8, 2020, by age group (per 100,000 people). [cited 2020 11/06/2020]; Available from: https://www.statista.com/statistics/1008677/coronavirus-death-rates-by-age-new-york-city/; 2020.
[11] Richardson S, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, JAMA 2020;323(20):2020–9. https://doi.org/10.1001/jama.2020.6775 Online ahead of print.
[12] Wang R, et al. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY) 2020;12(7):6049–57.
[13] DuMontier C, et al. Defining under-treatment and over-treatment in older adults with cancer: a scoping literature review. J Clin Oncol 2020;joijn2609.
[14] Kudrerer NM, et al. Clinical impact of COVID-19 on patients with cancer (CC19): a cohort study. Lancet 2020;395(10241):1907–18.
[15] Garassino MC, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol 2020;21(7):914–22. https://doi.org/10.1016/S1470-2045(20)30314-4 Epub 2020 Jun 12.
[16] van Doremalen N, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. New England Journal of Medicine 2020;382(16):1564–7.
[80] Hofheinz RD, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012;13(6):579–88.
[81] Grothey A, et al. Duration of adjuvant chemotherapy for stage III colon cancer. New England Journal of Medicine 2018;378(13):1177–88.
[82] Hall PS, et al. Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastrointestinal cancer (AGGANC): the GO2 phase III trial. J Clin Oncol 2019;37(15_suppl):4006.
[83] Corre R, et al. Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non–small-cell lung cancer: the phase III randomised ESOGIA-GPCH-GCOP 08-02 study. J Clin Oncol 2016;34(13):1476–83.
[84] Dees EC, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 2000;18(6):521–9.
[85] Schild SE, et al. The outcome of combined-modality therapy for stage III non–small-cell lung cancer in the elderly. J Clin Oncol 2003;21(17):3201–6.
[86] Gómez H, et al. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 1998;16(7):2352–8.
[87] Toolkit. Providing oncology treatments in the outpatient setting; 2020.
[88] von Lilienfeld-Toal M, et al. Frequently asked questions regarding SARS-CoV-2 in cancer patients—recommendations for clinicians caring for patients with malignant diseases. Leukemia 2020;34(6):1487–94.
[89] Bos AC, et al. Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer. Eur J Cancer 2015;51(17):2553–61.
[90] Burdett S, et al. Adjuvant chemotherapy for resected early-stage non–small cell lung cancer. Cochrane Database Syst Rev 2020;2015(3):CD011430.
[91] Kupstas AR, et al. Effect of surgery type on time to adjuvant chemotherapy and im-
[92] Burdett S, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer: a systematic review and meta-analysis. JAMA Oncol 2016;2(11):1477–86.
[93] Powell IJ, et al. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109. J Urol 2002;168(5):2016–9.
[94] Scolieri MJ, Altman A, Resnick MI. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated? J Urol 2000;164(5):1465–72.
[95] Crivellari D, et al. Burdens of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol 2000;18(7):1412–22.
[96] Williams CP, et al. Importance of quality-of-life priorities and preferences surrounding treatment decision making in patients with cancer and oncology clinicians. Cancer 2020;126(15):3534–41. https://doi.org/10.1002/cncr.32961 Epub 2020 May 19.
[97] Policy Brief. The impact of COVID-19 on older persons; 2020.
[98] Two million reasons - the cancer survivorship agenda: Why we need to support people with or beyond cancer. London: Macmillan Cancer Support; 2008.
[99] Bluethmann SM, Mariotto AB, Rowland JL. Anticipating the “Silver tsunami”: prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Cancer Epidemiol Biomarkers Prev 2016;25(7):1029–36.
[100] Nekhlyudov L, et al. Addressing the needs of cancer survivors during the COVID-19 pandemic. J Cancer Surviv 2020:1–6.
[101] Stay physically active during self-quarantine. [27/06/2020]; Available from: https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/technical-guidance/stay-physically-active-during-self-quarantine; 2020.
[102] Scher KS, Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol 2012;30(17):2036–8.
[103] Waterhouse DM, et al. Early impact of COVID-19 on the conduct of oncology clinical trials and long-term opportunities for transformation: findings from an American society of clinical oncology survey. JCO Oncology Practice 2008;0(0)p. OP20.00275.
[104] de Paula BHR, et al. Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic. Lancet Oncol 2020;21(5):624–7.
[105] Fleming TR, Labriola D, Wittes J. Conducting clinical research during the COVID-19 pandemic: protecting scientific integrity. Jama 2020. https://doi.org/10.1001/jama.2020.0236 Online ahead of print.
[106] FDA. Guidance on conduct of clinical trials of medical products during COVID-19 public health emergency: guidance for industry, investigators, and institutional review boards. Food and Drug Administration; 2020.
[107] Guidance on the management of clinical trials during the COVID-19 (coronavirus) pandemic. European Medicines Agency; 2020.